Expression and Clinical Significance of YAP, TAZ, and AREG in Hepatocellular Carcinoma

Table 3

Cox regression analysis of overall survival (𝑛=39).

	𝑁=	Univariate analysis			Multivariate analysis
		HR	95% CI	𝑃	HR	95% CI	𝑃
YAP
Negative	12	1			1
Positive	27	0.279	(0.081−0.955)	0.042^∗	0.054	(0.007−0.413)	0.005^∗
TAZ
Negative	13	1			1
Positive	26	0.842	(0.323−2.194)	0.725	1.962	(0.514−7.499)	0.324
AREG
Negative	15	1			1
Positive	24	0.783	(0.324−1.893)	0.588	0.436	(0.144−1.321)	0.142
Age
<55	23	1			1
≥55	16	0.636	(0.264−1.532)	0.313	0.629	(0.182−2.176)	0.464
Sex
Men	35	1			1
Women	4	2.661	(0.356−19.894)	0.340	3.158	(0.330−30.219)	0.318
Tumor size, cm
≤5	19	1			1
>5	20	0.524	(0.208−1.317)	0.169	2.049	(0.325−12.896)	0.445
Edmonson grade
I + II	26	1			1
III	13	0.403	(0.167−0.975)	0.044^∗	0.846	(0.200−3.680)	0.820
Venous infiltration
Present	6	1			1
Absent	33	0.559	(0.186−1.680)	0.300	0.187	(0.025−1.422)	0.105
Hepatitis
Negative	9	1			1
HBV/HCV	30	1.692	(0.649−4.412)	0.282	8.851	(1.667−47.008)	0.010^∗
Serum AFP level, ng/mL
≤200	21	1			1
>200	18	0.896	(0.373−2.154)	0.896	1.141	(0.384−3.387)	0.812
TNM stage
I + II	15	1			1
III + IV	24	0.427	(0.155−1.179)	0.101	0.234	(0.036−1.511)	0.127
No. of tumor nodules
1	36	1			1
≥2	3	0.242	(0.069−0.844)	0.026^∗	0.143	(0.027−0.752)	0.022^∗

95% CI indicates 95% confidence interval.
∗Statistically significant.